Prof. Dr. Jens Huober
chief physician
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz M, Bourayou N, Smith I, Barriga S, Frenzel M, Forrester T, Garnica Jaliffe G, Freedman O, Manso L, Chen S, Trédan O, Park I, Huober J, Paluch-Shimon S, Sohn J, Campone M, Toi M, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35:3638-3646.
Oct 2, 2017MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Oct 2, 2017J Clin Oncol 2017; 35:3638-3646
Goetz Matthew P, Bourayou Nawel, Smith Ian C, Barriga Susana, Frenzel Martin, Forrester Tammy, Garnica Jaliffe Georgina, Freedman Orit C, Manso Luis, Chen Shin-Cheh, Trédan Olivier, Park In Hae, Huober Jens, Paluch-Shimon Shani, Sohn Joohyuk, Campone Mario, Toi Masakazu, Di Leo Angelo
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Hahnen E, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Neidhardt G, Schem C, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P, Blohmer J, Jackisch C, Paepke S, Gerber B, Kümmel S, Schmutzler R. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3:1378-1385.
Oct 1, 2017Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Oct 1, 2017JAMA Oncol 2017; 3:1378-1385
Hahnen Eric, Huober Jens, Rhiem Kerstin, Costa Serban, Altmüller Janine, Hanusch Claus, Thiele Holger, Müller Volkmar, Nürnberg Peter, Karn Thomas, Nekljudova Valentina, Untch Michael, von Minckwitz Gunter, Neidhardt Guido, Schem Christian, Lederer Bianca, Hauke Jan, Loibl Sibylle, Kröber Sandra, Schneeweiss Andreas, Denkert Carsten, Fasching Peter A, Blohmer Jens U, Jackisch Christian, Paepke Stefan, Gerber Bernd, Kümmel Sherko, Schmutzler Rita K
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
van Mackelenbergh M, Weber K, von Minckwitz G, Untch M, Schneeweiss A, Müller V, Kümmel S, Blohmer J, Fasching P, Huober J, Hanusch C, Jackisch C, Stickeler E, Marme F, Schem C, Karn T, Nekljudova V, Denkert C, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat 2017; 167:59-71.
Sep 5, 2017Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
Sep 5, 2017Breast Cancer Res Treat 2017; 167:59-71
van Mackelenbergh Marion T, Weber Karsten E, von Minckwitz Gunter, Untch Michael, Schneeweiss Andreas, Müller Volkmar, Kümmel Sherko, Blohmer Jens-Uwe, Fasching Peter A, Huober Jens, Hanusch Claus, Jackisch Christian, Stickeler Elmar, Marme Frederik, Schem Christian, Karn Thomas, Nekljudova Valentina, Denkert Carsten, Loibl Sibylle
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober J, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 2017; 28:1803-1810.
Aug 1, 2017German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Aug 1, 2017Ann Oncol 2017; 28:1803-1810
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober Jens, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H-J, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Kümmel S, Burchardi N, von Minckwitz G, Fasching P, Klare P, Engels K, Denkert C, Schneeweiss A, Jackisch C, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Blohmer J, Untch M, Schem C, Huober J, Paepke S, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer 2017; 84:1-8.
Jul 30, 2017Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Jul 30, 2017Eur J Cancer 2017; 84:1-8
Kümmel Sherko, Burchardi Nicole, von Minckwitz Gunter, Fasching Peter A, Klare Peter, Engels Knut, Denkert Carsten, Schneeweiss Andreas, Jackisch Christian, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Blohmer Jens Uwe, Untch Michael, Schem Christian, Huober Jens, Paepke Stefan, Loibl Sibylle
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Riethdorf S, Untch M, von Minckwitz G, Schem C, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Weber K, Nekljudova V, Loibl S, Müller V, Pantel K. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res 2017; 23:5384-5393.
Jul 5, 2017Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Jul 5, 2017Clin Cancer Res 2017; 23:5384-5393
Riethdorf Sabine, Untch Michael, von Minckwitz Gunter, Schem Christian, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Weber Karsten, Nekljudova Valentina, Loibl Sibylle, Müller Volkmar, Pantel Klaus
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
Untch M, Luftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Kühn T, Janni W, Gerber B, Huober J, Jackisch C, Schneeweiss A, Brucker S, Dall P, Denkert C, Fasching P, Fehm T, Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Frauenheilkd 2017; 77:633-644.
Jun 28, 2017Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
Jun 28, 2017Geburtshilfe Frauenheilkd 2017; 77:633-644
Untch Michael, Luftner Diana, Möbus Volker, Müller Volkmar, Rody Achim, Sinn Peter, Thill Marc, Thomssen Christoph, Harbeck Nadia, Kühn Thorsten, Janni Wolfgang, Gerber Bernd, Huober Jens, Jackisch Christian, Schneeweiss Andreas, Brucker Sara Y, Dall Peter, Denkert Carsten, Fasching Peter A, Fehm Tanja, Liedtke Cornelia
CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
Ettl J, Huober J, Luftner D, Marme F, Würstlein R. CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer. Breast Care (Basel) 2017; 12:118-120.
Apr 26, 2017CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
Apr 26, 2017Breast Care (Basel) 2017; 12:118-120
Ettl Johannes, Huober Jens, Luftner Diana, Marme Frederik, Würstlein Rachel
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2017; 23:4323-4334.
Apr 5, 2017HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Apr 5, 2017Clin Cancer Res 2017; 23:4323-4334
Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L
Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study
Schulz S, Laszlo R, Otto S, Prokopchuk D, Schumann U, Ebner F, Huober J, Steinacker J. Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study. Disabil Rehabil 2017; 40:1501-1508.
Mar 21, 2017Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study
Mar 21, 2017Disabil Rehabil 2017; 40:1501-1508
Schulz Sebastian Viktor Waldemar, Laszlo Roman, Otto Stephanie, Prokopchuk Dmytro, Schumann Uwe, Ebner Florian, Huober Jens, Steinacker Jürgen Michael
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Fumagalli D, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase J, Huober J, Baselga J, Piccart M, Loi S, Coccia-Portugal M, Chang T, Gomez H, Venet D, Ignatiadis M, Azim H, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2017; 3:227-234.
Feb 1, 2017RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Feb 1, 2017JAMA Oncol 2017; 3:227-234
Fumagalli Debora, Di Cosimo Serena, de Azambuja Evandro, de la Pena Lorena, Nuciforo Paolo, Brase Jan C, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Coccia-Portugal Maria Antonia, Chang Tsai-Wang, Gomez Henry, Venet David, Ignatiadis Michail, Azim Hatem A, Maetens Marion, Rothé Françoise, Salgado Roberto, Bradbury Ian, Pusztai Lajos, Harbeck Nadia, Sotiriou Christos
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Reinisch M, Nekljudova V V, Untch M, Lederer B, Rhiem K, Schneeweiss A, Kümmel S, Jackisch C, Hanusch C, Denkert C, Blohmer J, von Minckwitz G, Huober J, Loibl S. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast 2017; 32:73-78.
Jan 5, 2017pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Jan 5, 2017Breast 2017; 32:73-78
Reinisch Mattea, Nekljudova V Valentina, Untch Michael, Lederer Bianca, Rhiem Kerstin, Schneeweiss Andreas, Kümmel Sherko, Jackisch Christian, Hanusch Claus, Denkert Carsten, Blohmer Jens-Uwe, von Minckwitz Gunter, Huober Jens, Loibl Sibylle
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
Jan 1, 2017Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Jan 1, 2017Ann Oncol 2017; 28:2899
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsky P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer 2016; 64:12-21.
Jun 17, 2016Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
Jun 17, 2016Eur J Cancer 2016; 64:12-21
von Minckwitz G, Jackisch C, Kümmel S, Fasching P A, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober Jens, Gerber B, Zahm D M, Hilfrich J, Costa S D, Dubsky P, Blohmer J U, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
Apr 4, 2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Apr 4, 2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Janni W, Friedl T, Zwingers T, Huober J, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. Br J Cancer 2016; 114:863-71.
Mar 31, 2016Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Mar 31, 2016Br J Cancer 2016; 114:863-71
Janni W, Friedl T W P, Zwingers T, Huober Jens, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Baselga J, de Haas S, Olsen S, Samant M, Guardino A, Huober J, Ro J, Verma S, Lewis Phillips G, Pegram M. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 2016; 22:3755-63.
Feb 26, 2016Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Feb 26, 2016Clin Cancer Res 2016; 22:3755-63
Baselga José, de Haas Sanne L, Olsen Steve, Samant Meghna K, Guardino Alice E, Huober Jens, Ro Jungsil, Verma Sunil, Lewis Phillips Gail D, Pegram Mark D
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates R, Kreipe H, Hartmann A, Pelz E, Erber R, Harbeck N. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 2016; 27:1035-1040.
Feb 18, 2016Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Feb 18, 2016Ann Oncol 2016; 27:1035-1040
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober Jens, Peyro-Saint-Paul H, Kates R E, Kreipe H H, Hartmann A, Pelz E, Erber R, Harbeck N
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Loibl S, Untch M, von Minckwitz G, Mehta K, Jackisch C, Tiemann K, Fasching P, Pfitzner B, Eidtmann H, Hartmann A, Lederer B, Furlanetto J, Klimowicz A, Huober J, Darb-Esfahani S, Denkert C. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res 2016; 22:2675-83.
Jan 12, 2016Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Jan 12, 2016Clin Cancer Res 2016; 22:2675-83
Loibl Sibylle, Untch Michael, von Minckwitz Gunter, Mehta Keyur, Jackisch Christian, Tiemann Katharina, Fasching Peter A, Pfitzner Berit, Eidtmann Holger, Hartmann Arndt, Lederer Bianca, Furlanetto Jenny, Klimowicz Alexander, Huober Jens, Darb-Esfahani Silvia, Denkert Carsten
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
Marme F, von Minckwitz G, Untch M, Paepke S, Loibl S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer J, Lederer B, Schneeweiss A. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2015; 53:65-74.
Dec 13, 2015Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
Dec 13, 2015Eur J Cancer 2015; 53:65-74
Marme Frederik, von Minckwitz Gunter, Untch Michael, Paepke Stefan, Loibl Sibylle, Kümmel Sherko, Jackisch Christian, Huober Jens, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eidtmann Holger, Denkert Carsten, Costa Serban Dan, Blohmer Jens-Uwe, Lederer Bianca, Schneeweiss Andreas